Briseid K, Falkum A, Qvigstad E K, Stien R
Acta Neurol Scand. 1976 Oct;54(4):301-11. doi: 10.1111/j.1600-0404.1976.tb04361.x.
Estimates of prekallikrein levels in plasma specimens from patients with migraine and from healthy individuals were obtained by determining the benzoyl-arginine ethyl ester (BAEe) esterase activities developed on activation with kaolin, as suggested by Costerase level- 'n the patients and in the control material, and kinetic data provided no evidence of a difference in inhibitor levels. Only very low BAEe esterase activity was registered in samples of cerebrospinal fluid obtained from the patients and no significant difference between attacks and free intervals was detected. When citrated EDTA-treated plasma was activated with acetone-incubated normal plasma containing prekallikrein activator (factor XIIf), no significant difference in BAEe esterase activity was noticed between plasma from the patients and that from the control persons. When, however, citrated plasma without EDTA was used, a significantly higher peak level of esterase activity was registered in the patient plasma. This observation might suggest the presence of a factor positioned between active factor XII and prekallikrein, and present in higher amounts in plasma from patients with migraine than in healthy individuals.
按照科斯特酯水平测定法的建议，通过测定高岭土激活后血浆标本中产生的苯甲酰精氨酸乙酯（BAEe）酯酶活性，得出偏头痛患者和健康个体血浆标本中前激肽释放酶水平的估计值。患者组和对照材料中的动力学数据未显示抑制剂水平存在差异。从患者获得的脑脊液样本中仅记录到非常低的BAEe酯酶活性，且未检测到发作期和缓解期之间的显著差异。当用含有前激肽释放酶激活剂（因子XIIf）的丙酮孵育正常血浆激活枸橼酸乙二胺四乙酸（EDTA）处理的血浆时，患者血浆和对照者血浆之间的BAEe酯酶活性未发现显著差异。然而，当使用不含EDTA的枸橼酸血浆时，患者血浆中酯酶活性的峰值水平显著更高。这一观察结果可能表明存在一种位于活性因子XII和前激肽释放酶之间的因子，且偏头痛患者血浆中的含量高于健康个体。
